Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q3 2021 · 10-Q
Revenue$286.30M$286.30M−25.7% vs Q3 2020 Net Income-$40.40M-$40.40MN/M vs Q3 2020 EPS Diluted-$0.75-$0.75N/M vs Q3 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived$16,700,000−84.1% Free Cash Flowderived-$38,500,000N/M Margins · derivedGross margin33.0%
Operating margin-15.6%−31.5 pt vs Q3 2020
Net margin-14.1%−24.4 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 5, 2021 · 36 d after period end